Oragenics (OGEN) Competitors $0.19 +0.00 (+1.05%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.19 0.00 (0.00%) As of 05/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock OGEN vs. XFOR, RLMD, GLYC, BFRG, PMN, CING, ALLR, GOVX, FLGC, and TRIBShould you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include X4 Pharmaceuticals (XFOR), Relmada Therapeutics (RLMD), GlycoMimetics (GLYC), Bullfrog AI (BFRG), ProMIS Neurosciences (PMN), Cingulate (CING), Allarity Therapeutics (ALLR), GeoVax Labs (GOVX), Flora Growth (FLGC), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry. Oragenics vs. X4 Pharmaceuticals Relmada Therapeutics GlycoMimetics Bullfrog AI ProMIS Neurosciences Cingulate Allarity Therapeutics GeoVax Labs Flora Growth Trinity Biotech Oragenics (NYSE:OGEN) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk. Which has better valuation & earnings, OGEN or XFOR? Oragenics has higher earnings, but lower revenue than X4 Pharmaceuticals. Oragenics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOragenics$40K103.08-$20.66M-$1.12-0.17X4 Pharmaceuticals$31.36M0.63-$101.17M$2.141.58 Is OGEN or XFOR more profitable? X4 Pharmaceuticals' return on equity of -236.19% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets OragenicsN/A -2,087.95% -486.56% X4 Pharmaceuticals N/A -236.19%-75.14% Which has more volatility & risk, OGEN or XFOR? Oragenics has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Does the MarketBeat Community favor OGEN or XFOR? X4 Pharmaceuticals received 80 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 68.38% of users gave X4 Pharmaceuticals an outperform vote while only 0.00% of users gave Oragenics an outperform vote. CompanyUnderperformOutperformOragenicsOutperform VotesNo VotesUnderperform Votes55100.00% X4 PharmaceuticalsOutperform Votes8068.38% Underperform Votes3731.62% Does the media favor OGEN or XFOR? In the previous week, X4 Pharmaceuticals had 1 more articles in the media than Oragenics. MarketBeat recorded 1 mentions for X4 Pharmaceuticals and 0 mentions for Oragenics. X4 Pharmaceuticals' average media sentiment score of 1.44 beat Oragenics' score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Oragenics Neutral X4 Pharmaceuticals Positive Do analysts prefer OGEN or XFOR? X4 Pharmaceuticals has a consensus price target of $72.33, suggesting a potential upside of 2,033.73%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Oragenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oragenics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00X4 Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in OGEN or XFOR? 18.7% of Oragenics shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 4.9% of Oragenics shares are owned by company insiders. Comparatively, 2.4% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryX4 Pharmaceuticals beats Oragenics on 12 of the 17 factors compared between the two stocks. Get Oragenics News Delivered to You Automatically Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGEN vs. The Competition Export to ExcelMetricOragenicsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$4.12M$6.51B$5.38B$19.54BDividend YieldN/A2.64%5.28%3.90%P/E Ratio-0.038.7727.0134.99Price / Sales103.08254.76392.0635.84Price / CashN/A65.8538.2517.51Price / Book0.316.426.774.77Net Income-$20.66M$142.98M$3.22B$1.02B7 Day Performance-4.95%1.32%0.20%-0.35%1 Month Performance-2.54%2.28%8.04%6.15%1 Year Performance-91.35%1.11%19.45%6.57% Oragenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGENOragenicsN/A$0.19+1.1%N/A-91.4%$4.12M$40,000.00-0.035XFORX4 Pharmaceuticals4.5715 of 5 stars$2.92flat$72.33+2,377.2%-87.5%$16.90M$31.36M-32.4480Positive NewsRLMDRelmada Therapeutics4.4486 of 5 stars$0.51+10.4%$4.25+735.0%-78.3%$16.90MN/A-0.1810Positive NewsGLYCGlycoMimetics2.2453 of 5 stars$0.26+5.2%N/A-15.3%$16.77M$10,000.00-0.5650Positive NewsBFRGBullfrog AI1.3275 of 5 stars$1.74-0.6%N/A-39.3%$16.38M$60,000.00-2.054Positive NewsPMNProMIS Neurosciences2.3024 of 5 stars$0.50-2.7%$4.50+800.0%-69.4%$16.34MN/A-5.005Positive NewsGap UpCINGCingulate1.7254 of 5 stars$3.81-0.3%$25.75+575.9%+365.3%$16.18MN/A-0.4520Analyst ForecastALLRAllarity Therapeutics0.2756 of 5 stars$1.07+2.9%N/A-94.5%$16.14MN/A0.0010GOVXGeoVax Labs2.9687 of 5 stars$1.02+3.6%$11.10+988.2%-37.9%$15.50M$5.59M-0.2810News CoverageFLGCFlora Growth3.1445 of 5 stars$0.67-1.6%$4.00+501.5%-48.4%$15.25M$53.26M-0.68280Positive NewsTRIBTrinity Biotech0.6453 of 5 stars$0.82-3.2%N/A-60.3%$14.80M$59.13M-0.36480 Related Companies and Tools Related Companies X4 Pharmaceuticals Competitors Relmada Therapeutics Competitors GlycoMimetics Competitors Bullfrog AI Competitors ProMIS Neurosciences Competitors Cingulate Competitors Allarity Therapeutics Competitors GeoVax Labs Competitors Flora Growth Competitors Trinity Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGEN) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OGEN Stock Free OGEN Stock Alerts